Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
Subscribe To Our Newsletter & Stay Updated
